N-(2-Ketobutyl)propionsaeureamid | 40953-04-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2-Ketobutyl)propionsaeureamid
• 英文别名: N-(2-oxobutyl)propanamide
• CAS: 40953-04-6
• 化学式: C₇H₁₃NO₂
• mdl: MFCD19218470
• 分子量: 143.186
• InChiKey: JDDMJRMMPVYDMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-Ketobutyl)propionsaeureamid 在 palladium dihydroxide 、 氢气 、 sodium hydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， -20.0~50.0 ℃ 、379.21 kPa 条件下， 生成 N-[1-(1H-1,2,3-triazol-4-yl)-3-oxo-2-pentyl]propanamide
  参考文献：
  名称：

  α₂ Adrenoceptor Agonists as Potential Analgesic Agents. 1. (Imidazolylmethyl)oxazoles and -thiazoles

  摘要：

  A series of (imidazolylmethyl)oxazoles and -thiazoles were prepared and evaluated as alpha(2) adrenoceptor agonists. These compounds were also tested in in vivo paradigms that are predictive of analgesic activity. Variations in both the imidazole and thiazole portions of the molecule were investigated. Some of the more potent compounds such as 22, 26, 45, and 53 displayed at receptor binding in the 10-20 nM range and also had significant, antinociceptive activity in the mouse abdominal irritant test (MAIT).

  DOI：

  10.1021/jm990005a
• 作为产物：
  描述：

  丙酸酐 、 聚甘氨酸 在 吡啶 作用下， 以59%的产率得到N-(2-Ketobutyl)propionsaeureamid
  参考文献：
  名称：

  Studies on Organophosphorus Compounds 55. A New and Facile Synthetic Route to 1-Alkyl(Aryl)-2-amino-1-hydroxyalkylphosphonic Acids

  摘要：

  将亚磷酸二甲酯与通过达金-韦斯特反应（涉及相应的δ-氨基酸和酸酐的反应）方便地制备的酰氨基酮进行亲核加成，然后进行水解，就能以令人满意的收率得到 1-烷基（芳基）-2-氨基-1-羟基烷基膦酸。

  DOI：

  10.1055/s-1992-26154

文献信息

• CONJUGATES AND THEIR USES IN MOLECULAR IMAGING
  申请人：Ballinger James Russell

  公开号：US20140056810A1

  公开（公告）日：2014-02-27

  The present invention relates to bifunctional compounds, the bifunctional compounds for use in molecular imaging and therapy, methods of molecular imaging using the bifunctional compounds and kits including the bifunctional compounds for use molecular imaging. The bifunctional compounds have a tripodal hydroxypyridinone chelating portion and may be conjugated to a targeting group so that the compounds target specific cells or tissues in a subject.

  本发明涉及双功能化合物，该双功能化合物用于分子成像和治疗，使用该双功能化合物进行分子成像的方法以及包括用于分子成像的双功能化合物的试剂盒。这些双功能化合物具有三脚架羟基吡啶酮螯合部分，并且可以与靶向基团偶联，以使化合物靶向主体中的特定细胞或组织。
• Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors
  申请人：Traquandi Gabriella

  公开号：US20090124605A1

  公开（公告）日：2009-05-14

  Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明公开了式(Ia)或(Ib)的吡唑喹唑啉衍生物及其药学上可接受的盐，以及其制备方法和包含它们的制药组合物；本发明的化合物在治疗与蛋白激酶活性失调有关的疾病，如癌症中可能有用。
• Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
  申请人：Traquandi Gabriella

  公开号：US20070185143A1

  公开（公告）日：2007-08-09

  Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention maybe useful in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer”.

  本发明公开了公式（Ia）或（Ib）中定义的吡唑并[3,4-d]喹唑啉衍生物及其药学上可接受的盐，其制备方法和包含它们的制药组合物；本发明中的化合物可能在治疗中有用，用于治疗与蛋白激酶活性失调有关的疾病，如癌症。
• COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
  申请人：Shalwitz Robert

  公开号：US20120128625A1

  公开（公告）日：2012-05-24

  Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.

  本发明揭示了预防癌细胞转移的方法。所揭示的化合物可用于预防肿瘤或其他类型的癌细胞扩散。
• COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
  申请人：Peters Kevin Gene

  公开号：US20120129847A1

  公开（公告）日：2012-05-24

  Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like.

  本发明公开了治疗眼部疾病或病症的方法，特别是视网膜病变、眼部水肿和眼部新生血管形成。这些疾病或病症的非限制性示例包括糖尿病性黄斑水肿、老年性黄斑变性（湿性）、脉络膜新生血管形成、糖尿病性视网膜病变、视网膜静脉阻塞（中央或分支）、眼部创伤、手术引起的水肿、手术引起的新生血管形成、囊样黄斑水肿、眼部缺血、葡萄膜炎等。